TABLE 1.
Baseline clinical data.
| Baseline data | ARNI | ARB | Differences between ARNI and ARB |
| Basic information | |||
| Age | 67.26 ± 11.97 | 65.2 ± 9.79 | P = 0.434 |
| Male gender | 22/35 | 22/35 | P > 0.999 |
| Height (cm) | 166.03 ± 8.48 | 166.89 ± 9.44 | P = 0.691 |
| Weight (kg) | 70.46 ± 12.34 | 72.16 ± 13.47 | P = 0.584 |
| BMI (kg/m2) | 25.47 ± 3.56 | 25.78 ± 3.38 | P = 0.716 |
| Current smoker | 16/35 | 20/35 | P = 0.339 |
| Current drinker | 15/35 | 18/35 | P = 0.473 |
| Perioperative medications | |||
| Statin | 18/35 | 20/35 | P = 0.631 |
| SGLT-2i | 6/35 | 4/35 | P = 0.495 |
| Spironolactone | 9/35 | 1/35 | P = 0.006 |
| Preoperative anti-arrhythmic drugs | |||
| β-Blocker | 21/35 | 17/35 | P = 0.337 |
| Amiodarone | 2/35 | 3/35 | P = 0.643 |
| Postoperative anti-arrhythmic drugs | |||
| β-Blocker | 1/35 | 1/35 | P > 0.999 |
| Amiodarone | 32/35 | 29/35 | P = 0.284 |
| Propafenone | 2/35 | 5/35 | P = 0.232 |
| Medical history | |||
| Persistent AF | 16/35 | 10/35 | P = 0.138 |
| Hypertension | 31/35 | 33/35 | P = 0.393 |
| Diabetes mellitus | 16/35 | 19/35 | P = 0.473 |
| Hyperlipidemia | 24/35 | 27/35 | P = 0.420 |
| CHF | 16/35 | 14/35 | P = 0.809 |
| MI | 3/35 | 2/35 | P = 0.643 |
| Revascularization | 8/35 | 3/35 | P = 0.101 |
| PVD | 4/35 | 2/35 | P = 0.393 |
| Stroke/TIA | 14/35 | 11/35 | P = 0.454 |
| COPD | 5/35 | 3/35 | P = 0.452 |
| CKD | 4/35 | 3/35 | P = 0.690 |
| OSAHS | 1/35 | 3/35 | P = 0.303 |
| CHA2DS2-VASc | 3.54 ± 1.74 | 3.20 ± 1.53 | P = 0.384 |
| Baseline clinical data | |||
| HR (beats per minute) | 83.14 ± 20.34 | 80.03 ± 15.75 | P = 0.476 |
| SBP (mmHg) | 131.49 ± 16.54 | 133.91 ± 15.66 | P = 0.530 |
| DBP (mmHg) | 76.74 ± 15.88 | 73.77 ± 14.10 | P = 0.411 |
| Hemoglobin (g/L) | 137.54 ± 18.48 | 139.43 ± 18.81 | P = 0.674 |
| Serum creatinine (μmol/L) | 88.49 ± 38.97 | 76.66 ± 16.52 | P = 0.103 |
| eGFR (ml/min/1.73 m2) | 77.11 ± 23.21 | 84.31 ± 14.54 | P = 0.126 |
| Serum potassium (mmol/L) | 3.98 ± 0.30 | 4.11 ± 0.37 | P = 0.108 |
Baseline characters had no statistical difference between two groups, except for usage of spironolactone.
BMI, body mass index; SGLT-2i, sodium-dependent glucose transporters inhibitor; AF, atrial fibrillation; CHF, congestive heart failure; MI, myocardial infarction; PVD, peripheral vascular; TIA, transient ischemia attack; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; OSAHS, obstructive sleep apnea-hypopnea syndrome; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; RFCA, radiofrequency catheter ablation.